Search Results
Apr 28, 2026, 08:00 ET AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata
pill (systemic therapy) when your healthcare provider does not recommend TNF blockers. Adults with moderate to severe Crohn's disease (CD) when 1 or more medicines called TNF blockers have been used and did not work well or could not be tolerated, or after taking a different injection
More news about: AbbVie
Apr 28, 2026, 07:00 ET BANKFIRST CAPITAL CORPORATION Reports First Quarter 2026 Earnings of $8.39 Million
Alabama. BankFirst offers a wide variety of services for businesses and consumers. The Bank also offers internet banking, no-fee ATM access, checking, CD, and money market accounts, merchant services, mortgage loans, remote deposit capture, and more. For more information, visit
More news about: BankFirst Capital Corporation
Apr 27, 2026, 17:49 ET InsCorp, Inc. Reports Results for 1Q26
away from higher-cost CDs and toward core relationship balances, reflecting the focus and execution of our client-facing team members," Smith continued. CD balance growth of -3% Y/Y and LQ in 1Q26 resulted in a mix of 51% of deposits, down from 54% a quarter ago and 62% a year ago. INSBANK's loan-to-deposit
More news about: INSBANK
Apr 27, 2026, 08:05 ET AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease
approved by the FDA to treat adults with moderately to severely active CD. AbbVie anticipates FDA approval for this new dosing regimen for SKYRIZI later this year. If approved, patients with moderately to severely active CD would have a choice to receive their SKYRIZI induction via SC injection or
More news about: AbbVie
Apr 27, 2026, 08:00 ET RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
positive safety and efficacy results achieved in the Phase 3 study of RHB-104 in CD, with its potential further demonstrated using mucosal healing imaging, considered to be the gold standard for efficacy evaluation in CD.Paradigm shift in MAP-positive Crohn's disease treatment approach In
More news about: RedHill Biopharma Ltd.
Apr 27, 2026, 07:30 ET ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026
(ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA® (loncastuximab tesirine-lpyl).ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed
More news about: ADC Therapeutics SA
Apr 27, 2026, 06:47 ET Cellenkos, Inc. Announces FDA Clearance to Initiate Phase 2 Clinical Trial of CK0801 (Allogeneic Cord Blood-Derived Tregs) for Aplastic Anemia
chaos, by driving Four Rs:Resolve bone marrow inflammation: Decreases harmful monocytes and cytotoxic CD8+ T cells and interrupts the vicious cycle of immune-mediated destruction of hematopoietic stem cells.Reset Immune system. Support
More news about: Cellenkos, Inc.
Apr 27, 2026, 06:21 ET Cellenkos, Inc. Announces FDA Clearance to Initiate Phase 2 Clinical Trial of CK0801 (Allogeneic Cord Blood-Derived Tregs) for Aplastic Anemia
chaos, by driving Four Rs:Resolve bone marrow inflammation: Decreases harmful monocytes and cytotoxic CD8+ T cells and interrupts the vicious cycle of immune-mediated destruction of hematopoietic stem cells.Reset Immune system. Support
More news about: Cellenkos, Inc.
Apr 24, 2026, 08:00 ET Miracell Demonstrates Cognition Impairment and Brain Function Improvement in Severe Alzheimer's Patients Using 'SMART M-CELL'-Based CD34+ Cell-Rich Autologous Blood Concentrate Therapy
mononuclear cells (PBMCs), including CD34+ cells and mesenchymal stem cell populations. Flow cytometry analysis showed that 0.5% to 1.5% of isolated mononuclear cells met adult stem cell criteria (ABSC: CD34⁺CD45dim, CD73⁺, CD105⁺, viability above 95%).The CD34+ cell-rich autologous blood concentrate
More news about: Miracell
Apr 24, 2026, 07:30 ET HanchorBio Selects Bloomberg to Strengthen its Strategic Intelligence Across Drug Development and Global Biopharma
with a 178-million-variant SIRPα phage-display library and iterative screening to eliminate variants that bind normal cells, enrich high-affinity tumor CD47 binders, and identify rare clones with minimal red blood cell binding. That early experience contributed to a broader company view: intelligence and
More news about: HanchorBio Inc.
Apr 23, 2026, 08:02 ET CREATE Medicines Doses First Patient in Phase 1/2 Study of MT-304, a First-in-Class Multi-immune In Vivo CAR Therapy Targeting HER2-Positive Solid Tumors
majority of HER2-positive breast and gastric cancers and represents an established oncology target. Preclinical data demonstrate superior activity over CD89-based CAR constructs, tumor regression in models refractory to CAR T and checkpoint inhibitors, enhanced immune infiltration, and durable tumor clearance
More news about: CREATE Medicines, Inc.
Apr 23, 2026, 08:00 ET Mozart Therapeutics Announces Positive Interim Phase 1 Data in Adults with Stage 3 Type I Diabetes
administered at 0.05 mg/kg (n=2) or 0.15 mg/kg (n=3). All 5 patients showed selective activation and proliferation of CD8 Treg, a reduction in the prevalence of pathogenic CD4 and CD8 T cells in peripheral blood, and reduced responses to autoantigen restimulation—collectively demonstrating proof-of-mechanism. T1D
More news about: Mozart Therapeutics
Apr 23, 2026, 08:00 ET Repertoire Immune Medicines Announces First Participant Dosed in Phase 1/2 Trial of RPTR-1-201, a T Cell-Targeted Immune Medicine for Advanced Solid Tumors
clinic."RPTR-1-201 is a TCR bispecific molecule comprised of an engineered TCR that binds with high affinity and precision to a tumor-selective epitope and an anti-CD3 moiety that engages and redirects T cells to kill tumor cells. In preclinical studies, RPTR-1-201 has demonstrated potent killing of both immunologically
More news about: Repertoire Immune Medicines
Apr 23, 2026, 07:00 ET Skymizer Taiwan Inc. Unveils Breakthrough Architecture Enabling Ultra-Large LLM Inference on a Single Card
AI, classified analysis); retail (service automation, inventory reasoning); software engineering (private code copilots, autonomous CI/CD); and semiconductor & IC design (on-prem RTL copilots, verification agents, design-knowledge retrieval over proprietary IP).Spotlight:
More news about: Skymizer Taiwan Inc.
Apr 23, 2026, 03:00 ET MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia
Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen to be approved in Australia for adults with relapsed or refractory follicular lymphoma (R/R FL)
More news about: Specialised Therapeutics
Apr 22, 2026, 11:00 ET Yadea Showcases High-Performance Electric Mobility at Motorbike Istanbul
high-quality and comfortable riding experience for daily use. It features an automotive-grade headlight system with a high beam brightness of up to 25,000 cd and illumination covering up to four lanes, improving night-time visibility. Additional highlights include hill descent control, 3C explosion-proof glass,
More news about: Yadea
Apr 22, 2026, 09:16 ET CleanStart Production Containers Now Run Shell-Less and Read-Only Without Changing a Single Line of Developer Code
container architecture for production environments, delivered through a new automated init binary that requires no changes to developer Dockerfiles, CI/CD pipelines, or deployment workflows.
More news about: CleanStart
Apr 22, 2026, 09:00 ET Phanes Therapeutics to Present Updated Phase 2 Clinical Trial Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline Treatment of Metastatic PDAC at the 2026 ASCO Annual Meeting
Title: Spevatamig (PT886), a claudin 18.2 (CLDN18.2)/CD47 bispecific antibody, in combination with gemcitabine plus nab-paclitaxel (GnP) in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma
More news about: Phanes Therapeutics, Inc.
Apr 22, 2026, 09:00 ET Pegrizeprument Granted Orphan Drug Designation for Prevention of Organ Rejection in Heart Transplant Patients
and blocks CD28-mediated effector-T cell costimulation, without blocking CTLA-4, an important protein found on T cells that naturally helps keep the body's immune responses in check. Pegrizeprument is, therefore, expected to have a dual mechanism of action where in a direct manner, it blocks CD28-mediated
More news about: Veloxis Pharmaceuticals
Apr 22, 2026, 08:30 ET ATRA DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026
with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one prior therapy including an anti-CD20 containing regimen." Atara said that "[t]he CRL indicates that the FDA is unable to approve the EBVALLO™ BLA in its present form" because, according
More news about: Faruqi & Faruqi, LLP
Apr 22, 2026, 08:00 ET Citi Wealth Unveils "Citi Sky" - An AI-Powered Member of the Citi Wealth Team, Built Using Google Cloud and Google DeepMind Technologies
launch:Financial guidance and support: Delivering timely guidance for clients, including prompts for bank certificate of deposit (CD) maturity events and the provision of market insights from Citi Wealth's Chief Investment Office. Conversational interaction: Enabling
More news about: Google Cloud
Apr 22, 2026, 08:00 ET RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026
Program Population Study. Med Sci Monit. 2020;26:e927218. Published 2020 Nov 29. doi:10.12659/MSM.927218.[7] Maines LW, Keller SN, Smith RA, Smith CD. Opaganib Promotes Weight Loss and Suppresses High-Fat Diet-Induced Obesity and Glucose Intolerance. Diabetes Metab Syndr Obes. 2025;18:969-983.
More news about: RedHill Biopharma Ltd.
Apr 22, 2026, 07:00 ET Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting
5827About Actimab-AActimab-A (lintuzumab-Ac225) is Actinium's lead CD33-targeted radiotherapy and the only CD33-targeted radiotherapy in clinical development for myeloid malignancies. Actimab-A pairs a humanized anti-CD33 monoclonal antibody (lintuzumab) with the potent alpha-emitter Actinium-225
More news about: Actinium Pharmaceuticals, Inc.
Apr 21, 2026, 12:03 ET Verismo Therapeutics Presents Preclinical Data at AACR 2026 for SynKIR™-310 KIR-CAR Indicating Superior Preclinical Activity in B Cell Malignancies and Early Clinical Efficacy
trial, evaluating SynKIR™-310 KIR-CAR in patients with relapsed/refractory B-NHL, such as FL, and including those who have or have not previously received CD19 CAR T therapies. See clinicaltrials.gov (
More news about: Verismo Therapeutics
Apr 21, 2026, 10:32 ET Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting
at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti‐CD38 monoclonal antibody (Xd).For the treatment of adult patients with relapsed or refractory diffuse large B‐cell lymphoma (DLBCL),
More news about: Karyopharm Therapeutics Inc.